SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | |||
|---|---|---|---|---|---|
Sep. 30, 2021 |
Mar. 31, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | |||||
| Share-based Payment Arrangement, Expense | $ 1,624,309 | $ 3,158,487 | |||
| Revenue | $ 0 | $ 0 | 0 | 20,000 | |
| Total internal and external clinical studies study expens | $ 1,638,000 | $ 3,308,000 | |||
| Common shares issuable upon the exercise of outstanding stock options and warrants | 6,164,573 | 2,969,338 | 6,164,573 | 2,969,338 | |
| Potentially dilutive securities | 52,957 | ||||
| Costs directly related to public securities offering | $ 143,377 | ||||
| Current federal deposit insurance | $ 250,000 | ||||
| Common shares from convertible debentures and related accrued interest | $ 957,234 | $ 957,234 | |||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Indirect expenses and cost incurred associated with services rendered by an entity during the reporting period. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for award under share-based payment arrangement. Excludes amount capitalized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of other research and development expense. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|